Biodesix (BDSX) Capital Expenditures (2019 - 2026)

Biodesix (BDSX) has reported Capital Expenditures for 8 consecutive years, with $81000.0 the latest figure, recorded in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $81000.0, up 9.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $266000.0 (down 91.34% YoY), and the FY2025 annual result was $259000.0, down 91.98% from the prior year.
• Capital Expenditures was $81000.0 for Q1 2026 at Biodesix, down from $86000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $7.7 million in Q1 2023 and troughed at $48000.0 in Q3 2025.
• Average Capital Expenditures over 5 years is $1.8 million, with a median of $329000.0 recorded in 2022.
• Year-over-year, Capital Expenditures jumped 2829.77% in 2023 and slumped 97.35% in 2025.
• Over 5 years, Capital Expenditures stood at $1.9 million in 2022, then soared by 54.61% to $3.0 million in 2023, then slumped by 71.88% to $839000.0 in 2024, then sank by 89.75% to $86000.0 in 2025, then fell by 5.81% to $81000.0 in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $81000.0 in Q1 2026, $86000.0 in Q4 2025, and $48000.0 in Q3 2025.